journal article·2018-11-12Open access

Novel microencapsulated probiotic blend for use in metabolic syndrome: design and in-vivo analysis

Umar Haris Iqbal, Susan Westfall, Satya Prakash

Abstract

The increasing prevalence of the metabolic syndrome has made it a medical issue that currently affects 1 in 5 Canadians. The metabolic syndrome is defined by risk factors that predispose an individual to diabetes and cardiovascular disease. Current forms of interventions have been inadequate as substantiated by the fact that the prevalence of metabolic syndrome has not reduced over the years. The objective of this study was to investigate the therapeutic benefits of a novel microencapsulated probiotic blend in treating the metabolic syndrome. Three probiotic strains were microencapsulated into alginate-polylysine-alginate (APA) microcapsules: L. rhamnosus NCIMB 6375, L. plantarum NCIMB 8826 and L. fermentum NCIMB 5221. From the results, it was observed that the microencapsulated probiotic blend significantly reduced serum total cholesterol, LDL cholesterol and triglyceride levels (reducing from 516 mg/dL to 379 mg/dL, 314 mg/dL to 231 mg/dL and 580 mg/dL to 270 mg/dL, respectively). In addition, the administration of the microencapsulated probiotic blend was found to favourably influence the gut microbiota, decreasing Firmicutes levels and increasing Bacteroidetes levels. Overall, this work demonstrates the potential a microencapsulated probiotic blend could have in targeting multiple risk factors of the metabolic syndrome; however, greater research is still needed.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Gut microbiota and health · Probiotics and Fermented Foods · Infant Health and Development

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering, Biomedical Technology and Cell Therapy Research Laboratory, Artificial Cells and Organs Research Centre, Faculty of Medicine, McGill University

Department of Experimental Medicine, Faculty of Medicine, McGill University

References (55)

Show source-provided references
1. 10.1161/CIRCULATIONAHA.109.19264410.1161/CIRCULATIONAHA.109.192644 ↗
2. Statistics-Canada. Metabolic syndrome in Canadians, 2009 to 2011. In: Division HS, editor. Canada: Minister of Industry; 2012.
3. 10.1001/archinte.163.4.42710.1001/archinte.163.4.427 ↗
4. 10.2337/diacare.26.12.323010.2337/diacare.26.12.3230 ↗
5. 10.1016/S0140-6736(05)67402-810.1016/S0140-6736(05)67402-8 ↗
6. 10.1001/jama.287.3.35610.1001/jama.287.3.356 ↗
7. 10.1177/088453361771318910.1177/0884533617713189 ↗
8. Miller ML, Wright CC. Use of lipid lowering medications in youth. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.
9. 10.1016/j.jff.2015.01.00910.1016/j.jff.2015.01.009 ↗
10. 10.1016/j.foodres.2016.10.04210.1016/j.foodres.2016.10.042 ↗
11. 10.1016/j.foodres.2015.07.01510.1016/j.foodres.2015.07.015 ↗
12. 10.1016/j.bbrc.2016.10.03110.1016/j.bbrc.2016.10.031 ↗
13. 10.1007/s00253-013-5252-810.1007/s00253-013-5252-8 ↗
14. 10.1038/nrgastro.2014.6610.1038/nrgastro.2014.66 ↗
15. 10.1038/nrgastro.2017.7510.1038/nrgastro.2017.75 ↗
16. 10.1258/ebm.2011.01039910.1258/ebm.2011.010399 ↗
17. Tsai CC, Lin PP, Hsieh YM, et al. Cholesterol-lowering potentials of lactic acid bacteria based on bile-salt hydrolase activity and effect of potent strains on cholesterol metabolism in vitro and in vivo. ScientificWorldJournal. 2014;2014:1.10.1155/2014/690752 ↗
18. 10.1016/j.atherosclerosis.2015.06.03010.1016/j.atherosclerosis.2015.06.030 ↗
19. 10.1002/oby.2042810.1002/oby.20428 ↗
20. 10.3390/ph502023610.3390/ph5020236 ↗
21. 10.1142/639510.1142/6395 ↗
22. 10.1371/journal.pone.005839410.1371/journal.pone.0058394 ↗
23. 10.1038/nm0896-88310.1038/nm0896-883 ↗
24. 10.1073/pnas.82.13.452610.1073/pnas.82.13.4526 ↗
25. 10.1111/1751-7915.1236810.1111/1751-7915.12368 ↗
26. 10.1046/j.1365-2036.2000.00763.x10.1046/j.1365-2036.2000.00763.x ↗
27. 10.3920/BM2015.002110.3920/BM2015.0021 ↗
28. 10.1155/2014/38031610.1155/2014/380316 ↗
29. 10.1002/jsfa.187310.1002/jsfa.1873 ↗
30. 10.1016/S0009-8981(02)00344-310.1016/S0009-8981(02)00344-3 ↗
31. 10.1080/0962935999051310.1080/09629359990513 ↗
32. 10.3164/jcbn.14-11610.3164/jcbn.14-116 ↗
33. 10.1371/journal.pone.018064810.1371/journal.pone.0180648 ↗
34. 10.1111/jam.1210510.1111/jam.12105 ↗
35. 10.1007/s00253-007-0908-x10.1007/s00253-007-0908-x ↗
36. 10.1155/2007/1368410.1155/2007/13684 ↗
37. 10.1016/S0014-2999(01)01249-310.1016/S0014-2999(01)01249-3 ↗
38. 10.1016/j.metabol.2013.08.00110.1016/j.metabol.2013.08.001 ↗
39. 10.1194/jlr.M03052810.1194/jlr.M030528 ↗
40. 10.1016/S0022-2275(20)36896-610.1016/S0022-2275(20)36896-6 ↗
41. Zak B, Luz DA, Fisher M. Determination of serum cholesterol. Am J Med Technol. 1957;23:283–287.
42. 10.1093/clinchem/28.6.137910.1093/clinchem/28.6.1379 ↗
43. Metabolic syndrome in adults 2012 to 2013 2015. Available from: http://www.statcan.gc.ca/pub/82-625-x/2014001/article/14123-eng.htm#n1.
44. 10.3168/jds.S0022-0302(99)75506-210.3168/jds.S0022-0302(99)75506-2 ↗
45. 10.1007/s12010-014-0839-910.1007/s12010-014-0839-9 ↗
46. 10.1128/AEM.00137-0810.1128/AEM.00137-08 ↗
47. 10.1021/jf960440310.1021/jf9604403 ↗
48. 10.1016/S0891-5849(01)00585-810.1016/S0891-5849(01)00585-8 ↗
49. 10.1104/pp.104.2.31510.1104/pp.104.2.315 ↗
50. 10.1055/s-2006-95806010.1055/s-2006-958060 ↗
51. 10.1002/iid3.17010.1002/iid3.170 ↗
52. 10.3727/00000000178398680010.3727/000000001783986800 ↗
53. 10.1152/ajpendo.00302.200610.1152/ajpendo.00302.2006 ↗
54. 10.1002/jat.347510.1002/jat.3475 ↗
55. 10.1038/4441022a10.1038/4441022a ↗